Pharma Marketletter

View more issues:

Articles in November, 2004 issue of Pharma Marketletter

• Pharma R&D remains vital to the UK
• Recordati's 3rd-qtr earnings rise 13%
• Shire Pharma sees 3rd-qtr net income rise 19%, but fails to inspire investors
• Sanofi-Aventis' 3rd-qtr sales rise 10.7%.
• Metabolic protein processing deficits may cause schizophrenia
• New Spanish Rx trade chief slams govt policies
• India's new patent bill expected to go before Parliament in December.
• 3rd-qtr profit for Chiron despite Fluvirin woes.
• IPMG joins fight against fake drugs in Indonesia - by P S Sujarto, Jakarta
  by P.S. Sujarto
• French Rx R&D losing ground, says Academy
• Spain: cash benefits from Rx innovation
• Tokyo pharma stocks - week to November 8.
• US patent challenge for Sanofi-Aventis' Plavix - the risks from Canada.
• Stock Commentary - New York.
• US employees keen to shoulder more health responsibility, but do not know how: study.
• Stock Commentary - New York.
• W Virginia Senate backs Rx cost management
• Patients in UK "get less Rx info than elsewhere"
• Omega-3 fats benefit cardiovascular health, more US research shows.
• Letter from the Editor
• Ahead of election, Bush pledges funds for cancer trials, Rx benefit promo in 21 states.
• New EORTC cancer guidelines focus on treating anemia
• "Big savings" from US Free Market Drug Act
• Richter Gedeon's nine-month profit grows 7%
• US sales decline hits Santen results
• Tokyo pharma stocks - week to November 15.
• Tokyo pharma stocks - week to October 25.
• UPDATE: Serono tops forecasts as EPS rockets 54%
• New Data confirm benefits of AstraZeneca's Crestor in treating broad range of patients.
• Daiichi sees first-half revenues fall 2%.
• World Rx sales up 7% in year to September
• Fast-growing RNAi market shows no sign of slowing, says study.
• UK MPs warned of the costs to society of "disease-mongering and risk factor creep"
• New FDA initiative to protect US drug supply through RFID.
• Stock Commentary - Europe
• Can poor nations help the rich contain Rx costs?
• CAT's fiscal 2004 revenues rocket 82%
• Editor's views: Vioxx fall-out; impact on AstraZeneca and pharma industry.
• Better lifecycle management essential for pharmaceutical industry success; new study.
• EpiTan focuses on Melanotan, a potential blockbuster Olife styleO drug.
• French antibiotics consumption falls 16% since 2002, with 25% target by 2008.
• Ranbaxy's 3rd-qtr 2004 sales jump 19%
• Merck KGaA's 3rd-qtr profit leaps 43%
• New UK pharmacy contract announced.
• US pharma groups tell Pres Bush of their needs.
• Serono showcases business and plays down rival drug at financial roadshow.
• Senetek signs letter of intent to buy IGI
• Stock Commentary - Europe
• California voters back stem cell research.
• Wyeth showcases novel antibiotic tigecycline, with activity against MRSA
• Promising Ph II data for Abbott's ABT-874.
• Spain mulling free "morning-after" pill
• New UK pharma commission members to be barred from links with industry.
• Canadian pharmacists/patients/seniors group backs govt on Internet pharmacy.
• Boehringer Ingelheim's tipranavir beats rival HIV drugs in a pivotal Phase III trial.
• Elan/Biogen Idec's Tysabri Oked by FDA.
• AstraZeneca to buy 19.9% stake in CAT alongside research deal to boost pipeline.
• US FDA "fiasco dispels 'branded = safe' spin".
• Perrigo to buy Israel's Agis in $818 million deal, to create global generics provider
• Pfizer and GSK drug anti-counterfeiting moves
• GSK/MedImmune's cervical cancer vaccine shows promise; Lancet study.
• S Africa Rx prices fall, but are patients benefiting?
• LEEM advances French biopharma proposals
• GSK reveals CNS research portfolio; highlights '381 and radafaxine.
• NIST begins new gene expression profiling program
• Strong 1st-half income growth for Takeda.
• Carl Icahn continues campaign to derail Mylan's planned acquisition of King Pharma.
• German drugmakers call for price rises
• NeuroSearch lifts 2004 target on 3rd-qtr results
• US uninsured "pay 78% more than best Rx prices".
• GlaxoSmithKline's profit drops again for 3rd qtr, on flagging sales and weak dollar
• Euro bio/generics mkt "to hit $21.2B in 2010".
• Indian govt committee reports on drug prices
• US FDA announces guidance for generics.
• Visually-impaired "find Rx labels, info too small".
• Sanofi-Aventis' Acomplia provides long-term cardiovascular benefits; two-year study.
• Editor's views on US HHS/FDA appointments; new UK regulatory agency
  by Barbara Obstoj
• Sankyo's 1st-half in line with forecasts.
• Stock Commentary - Tokyo.
• BIO urges US Congress to keep patent fees at PTO.

• 1
• 2